|

Farletuzumab ecteribulin Clinical Trials

1 actively recruiting trial across 1 location

Also known as: MORAb-202

Pipeline

Phase 1/2: 1

Top Sponsors

  • Eisai Inc.1

Indications

  • Solid Tumor1
  • Lung Cancer1
  • Breast Cancer1
  • Cancer1

Tucson, Arizona1 trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

ACRC/Arizona Clinical Research Center, Inc

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.